|
1
|
Jones AMK, Yue WY, Marcus J and Heller DS:
Pitfalls of frozen section in gynecological pathology: A case of
ovarian serous surface papillary adenofibroma imitating malignancy.
Int J Surg Pathol. 27:268–270. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Taylor EC, Irshaid L and Mathur M:
Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic
Correlation. Radiographics. 41:289–315. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cho DH: Serous cystadenofibroma
misdiagnosed as an ovarian malignancy. BMJ Case Rep 28:.
11(e228223)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Takeuchi M, Matsuzaki K and Harada M:
Ovarian adenofibromas and cystadenofibromas: Magnetic resonance
imaging findings including diffusion-weighted imaging. Acta Radiol.
54:231–236. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hsu I, Lee LH, Hsu L, Chen SU and Hsu CC:
Disordered hypothalamus-pituitary-ovary axis in heterotopic
extraovarian sex cord-stromal proliferation: A case report of
fallopian tube serous adenofibroma. BMC Womens Health.
23(243)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Roshini AP, Pandarinath A and Corriea M:
Serous papillary cystadenofibroma of vulva: A histopathological
surprise. Int J Surg Case Rep. 83(105776)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tavares MA, Silva RC, Lourenço M and
Ambrósio A: Giant serous adenofibroma of the fallopian tube. BMJ
Case Rep. 13(e234267)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ulker V, Tunca AF, Akbayir O, Numanoglu C,
Yesil S and Bakir B: Serous surface papillary adenofibroma of the
ovary: Impersonator of ovarian malignancy. J Obstet Gynaecol.
34:365–366. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Andreotti RF, Timmerman D, Strachowski LM,
Froyman W, Benacerraf BR, Bennett GL, Bourne T, Brown DL, Coleman
BG, Frates MC, et al: O-RADS US risk stratification and management
system: A consensus guideline from the ACR Ovarian-adnexal
reporting and data system committee. Radiology. 294:168–185.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sadowski EA, Thomassin-Naggara I, Rockall
A, Maturen KE, Forstner R, Jha P, Nougaret S, Siegelman ES and
Reinhold C: O-RADS MRI risk stratification system: Guide for
assessing adnexal lesions from the ACR O-RADS Committee. Radiology.
303:35–47. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Global BMIMC, Di Angelantonio E,
Bhupathiraju Sh N, Wormser D, Gao P, Kaptoge S, Berrington de
Gonzalez A, Cairns BJ, Huxley R, Jackson ChL, et al: Body-mass
index and all-cause mortality: Individual-participant-data
meta-analysis of 239 prospective studies in four continents.
Lancet. 388:776–786. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Thull T and Kempton D: Ovarian cancer: A
review for primary care providers. JAAPA. 37:32–36. 2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sasamoto N and Elias KM: Early detection
of ovarian cancer. Cold Spring Harb Perspect Med.
13(a041337)2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Virgilio BA, De Blasis I, Sladkevicius P,
Moro F, Zannoni GF, Arciuolo D, Mascilini F, Ciccarone F, Timmerman
D, Kaijser J, et al: Imaging in gynecological disease (16):
Clinical and ultrasound characteristics of serous cystadenofibromas
in adnexa. Ultrasound Obstet Gynecol. 54:823–830. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rocha RM and Barcelos IDES: Practical
recommendations for the management of benign adnexal masses. Rev
Bras Ginecol Obstet. 42:569–576. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Timmerman D, Ameye L, Fischerova D,
Epstein E, Melis GB, Guerriero S, Van Holsbeke C, Savelli L,
Fruscio R, Lissoni AA, et al: Simple ultrasound rules to
distinguish between benign and malignant adnexal masses before
surgery: Prospective validation by IOTA group. BMJ.
341(c6839)2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Oladimeji P, Skerl R, Rusch C and
Diakonova M: Synergistic activation of ERα by estrogen and
prolactin in breast cancer cells requires tyrosyl phosphorylation
of PAK1. Cancer Res. 76:2600–2611. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Alkharusi A, AlMuslahi A, AlBalushi N,
AlAjmi R, AlRawahi S, AlFarqani A, Norstedt G and Zadjali F:
Connections between prolactin and ovarian cancer. PLoS One.
16(e0255701)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jung D, Almstedt K, Battista MJ, Seeger A,
Jäkel J, Brenner W and Hasenburg A: Immunohistochemical markers of
prognosis in adult granulosa cell tumors of the ovary-a review. J
Ovarian Res. 16(50)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Davey MG, Hynes SO, Kerin MJ, Miller N and
Lowery AJ: Ki-67 as a prognostic biomarker in invasive breast
cancer. Cancers (Basel). 13(4455)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang L, Zheng L, Yang Q and Sun J: The
evolution of BRAF activation in Non-Small-Cell lung cancer. Front
Oncol. 12(882940)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Vang R, Shih IM and Kurman RJ: Ovarian
Low-grade and High-grade serous carcinoma: Pathogenesis,
clinicopathologic and molecular biologic features, and diagnostic
problems. Adv Anat Pathol. 16(267)2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liu S, Liu T, Jiang J, Guo H and Yang R:
p53 mutation and deletion contribute to tumor immune evasion. Front
Genet. 14(1088455)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mebratie DY and Dagnaw GG: Review of
immunohistochemistry techniques: Applications, current status, and
future perspectives. Semin Diagn Pathol. 41:154–160.
2021.PubMed/NCBI View Article : Google Scholar
|
